Ascendis Pharma revenue and financials

ASND · NASDAQ · USD

Compare Ascendis Pharma
$271.19Change from previous close: −0.20%Absolute change: −$0.54

Close · November 17, 2026

In the fiscal year ended December 2025, Ascendis Pharma reported revenue of €720.13M (+98.03% year over year). The net loss was €228.03M.

Annual revenue · 2025: €720.13M
  1. €4.61M2016
  2. €1.53M2017
  3. €10.58M2018
  4. €13.38M2019
  5. €6.95M2020
  6. €7.78M2021
  7. €51.17M2022
  8. €266.72M2023
  9. €363.64M2024
  10. €720.13M2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+98.03%
2025 vs 2024
Net margin
-31.7%
2024: -104.0%

How Ascendis Pharma is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue72036426751.27.87.013.410.61.54.6
Cost of revenue94.944.344.412.13.50.00.0———
Gross profit62531922239.04.37.013.410.61.54.6
Selling, general and administrative45829126421616076.748.525.113.511.5
Research and development30430741338029626119214099.666.0
Operating income-136-279-456-562-452-331-227-155-112-72.9
EBIT-136-279-456-547-452-331-227-155-112-72.9
EBITDA-131-274-437-529-437-321-225-154-111-72.2
Interest expense20710044.150.53.980.81.20.113.83.1
Pre-tax income-213-373-474-578-384-419-218-130-124-68.7
Income tax15.44.87.35.4-0.4-0.2-0.2-0.4-0.5-0.2
Net income-228-378-481-583-384-419-218-130-124-68.5
Net income to common shareholders-228-378-481-583-384-419-218-130-124-68.5
Basic EPS-3.76-6.53-8.55-10.40-7.00-8.28-4.69-3.17-3.68-2.58
Diluted EPS-3.76-6.53-8.55-10.40-7.00-8.28-4.69-3.17-3.68-2.58
Average shares (basic)60.657.956.356.154.850.646.541.133.626.6
Average shares (diluted)60.657.956.356.154.850.646.541.133.626.6

Companies in the group: same industry, similar size